menu
    • menu

    Company profile for Karyopharm Therapeutics

    NEW Drugs in Dev: 10
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer. Our company was founded in 2008 with a vision of pioneering a potentially new approach to treating patients with cancer and other serious diseases. Our novel approach to cancer treatment involves targeting the export of spe...
    Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer. Our company was founded in 2008 with a vision of pioneering a potentially new approach to treating patients with cancer and other serious diseases. Our novel approach to cancer treatment involves targeting the export of specific proteins in a cancer cell’s nucleus with SINE technology (Selective Inhibition of Nuclear Export). Our primary focus is on developing novel drugs which we hope will help treat patients with certain blood cancers.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Karyopharm TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    85 Wells Ave., 2nd floor Newton, MA 02459
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.karyopharm.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    SCOPE Summit

    SCOPE Summit

    Not Confirmed

    envelop Contact Supplier

    SCOPE Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Karyopharm Previews 2025 Revenue, Reiterates 2026 Guidance
    Karyopharm Previews 2025 Revenue, Reiterates 2026 Guidance

    12 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/karyopharm-announces-preliminary-unaudited-2025-revenue-and-reiterates-expectation-of-delivering-potentially-transformative-phase-3-data-in-2026-302658039.html

    PR NEWSWIRE
    12 Jan 2026
    Share Share
    Karyopharm Therapeutics Discloses Inducement Grants Per Nasdaq
    Karyopharm Therapeutics Discloses Inducement Grants Per Nasdaq

    03 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302648334.html

    PR NEWSWIRE
    03 Jan 2026
    Share Share
    Karyopharm Therapeutics Discloses Inducement Grants Per Nasdaq
    Karyopharm Therapeutics Discloses Inducement Grants Per Nasdaq

    01 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302629473.html

    PR NEWSWIRE
    01 Dec 2025
    Share Share
    Karyopharm Joins Piper Sandler 37th Annual Healthcare Conference
    Karyopharm Joins Piper Sandler 37th Annual Healthcare Conference

    01 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-the-piper-sandler-37th-annual-healthcare-conference-302624649.html

    PR NEWSWIRE
    01 Dec 2025
    Share Share
    Karyopharm Reveals Q3 2025 Financials And Company Advancements
    Karyopharm Reveals Q3 2025 Financials And Company Advancements

    03 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/karyopharm-reports-third-quarter-2025-financial-results-and-highlights-recent-company-progress-302601720.html

    PR NEWSWIRE
    03 Nov 2025
    Share Share
    Karyopharm Completes Ph3 SENTRY Trial Enrollment in Myelofibrosis
    Karyopharm Completes Ph3 SENTRY Trial Enrollment in Myelofibrosis

    10 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/karyopharm-announces-completion-of-enrollment-in-the-phase-3-sentry-trial-in-myelofibrosis-302551682.html

    PR NEWSWIRE
    10 Sep 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search